Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Status:
Terminated
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of
the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome
ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the
addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in
subjects who have residual disease, but have not progressed on ibrutinib after 18 months of
monotherapy, and/or prevents or delays disease progression of subjects with CLL.